Zilovertamab Vedotin Plus R-CHP Yields 97.2% Overall CR Rate in DLBCL
Patients with treatment naive DLBCL experienced high response rates when treated with zilovertamab vedotin plus R-CHP and a RP2D dose of the agent was selected.
Related Articles
Liso-Cel Shows Broad Spectrum Activity in CIBMTR Cohort of Relapsed/Refractory LBCL
Liso-cel demonstrated safety and efficacy outcomes that were comparable to those in the pivotal TRANSFORM and PILOT trials in patients with relapsed/refractory large B-cell lymphoma.
Blood Global Hematology | American Society of Hematology
Jorge Cortes, MD director of the Georgia Cancer Center at Augusta University and inaugural Editor-in-Chief of Blood Global Hematology, shares his vision for the journal…
The clinical significance of MRD in AL amyloidosis
In this video, Bruno Paiva, PhD, University of Navarra, Pamplona, Spain, discusses the clinical significance of measurable residual disease (MRD) in light-chain (AL) amyloidosis. Dr…
International Journal of Cancer Symposium on Principles of Chromatin Remodeling in Cancer and Translational Perspectives
Welcome to the International Journal of Cancer Symposium on Principles of Chromatin Remodeling in Cancer and Translational Perspectives Tight regulation of the spatial and temporal…
International Journal of Cancer Symposium on Principles of Chromatin Remodeling in Cancer and Translational Perspectives
Welcome to the International Journal of Cancer Symposium on Principles of Chromatin Remodeling in Cancer and Translational Perspectives Tight regulation of the spatial and temporal…
Adding blinatumomab to chemotherapy reduces recurrence risk in standard-risk paediatric B-ALL
Nature Reviews Clinical Oncology – Adding blinatumomab to chemotherapy reduces recurrence risk in standard-risk paediatric B-ALL
Government to publish a National Cancer Plan, as recommended by Health and Social Care Committee – Committees – UK Parliament
The Government has said that it will be publishing a National Cancer Plan, as recommended by the predecessor Health and Social Care Committee.
Navtemadlin Reduces Markers of Disease Burden in Relapsed/Refractory Myelofibrosis
Treatment with navtemadlin lowered the levels of biomarkers of disease burden in patients with relapsed/refractory myelofibrosis.
Fixed-Duration Acalabrutinib/Venetoclax Combo Improves PFS in Frontline CLL
Acalabrutinib plus venetoclax, with or without obinutuzumab, improved PFS over SOC chemoimmunotherapy in patients with treatment-naive CLL.
Biomarker-Guided Treatment Approaches Transform Lung and GI Cancer Management
Experts across the fields of lung and GI cancer share key information and insights from 2 recent OncLive biomarker consortiums.